Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells

Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, 80-90% of the patients who receive androgen ablation therapy ultimately develop recurrent tumors in 12-33 months after treatment with a median overall survival time of 1-2 years after relapse. LNCaP is a comm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lin, Hui-Ping, Lin, Ching-Yu, Hsiao, Ping-Hsuan, Wang, Horng-Dar, Sheng Jiang, Shih, Hsu, Jong-Ming, Jim, Wai-Tim, Chen, Marcelo, Kung, Hsing-Jien, Chuu, Chih-Pin
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2013
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3857776/
https://ncbi.nlm.nih.gov/pubmed/24349321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0082625
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados